JUN 1 3 2005

Carro Abo INTERNATIONAL	OF A DOLUMO ALITE	ODITY
From the INTERNATIONAL	. SEARUHING AUTE	IURII Y

PETTILLY AND COMPANY

To:			. • .	Patent Division	JEE
VOY, Gilbert P. O. Box 628 Indianapolis	38 IN 46206-6288	NOTIFICAT THE INTERNAT THE WRITTEN OF SEARCHING AUT	TONAL SEAR PINION OF TH	HE INTERNATION	DNAL
UNITED STATES	; OF AMERICA	22 Nov200	SPCT Rule	205 mod. 44.1) 94f	(z)e
		Date of mailing (day/month/year)	08/06/200	05 ·	
Applicant's or agent's	file reference				
X-16065		FOR FURTHER ACTION	ON See pa	aragraphs 1 and 4	below
International application		International filing date (day/month/year)	18/01/200	05	
Applicant			···		
ELI LILLY AND) COMPANY	W. 2000 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
Authority hav	nt is hereby notified that the international search ve been established and are transmitted herewi		ion of the Intern	ational Searching	
	endments and statement under Article 19: it is entitled, if he so wishes, to amend the claim	ns of the International Applic	cation (see Rule	46):	
	The time limit for filing such amendments is nor nternational Search Report; however, for more				
Where? Dire	1211 Geneva 20, Switzerland, Fa	scimile No.: (41-22) 740.1	4.35		
For more de	etailed instructions, see the notes on the acco	mpanying sheet.			
Article 17(2)(at is hereby notified that no international search (a) to that effect and the written opinion of the Ir	nternational Searching Auth	ority are transm	itted herewith.	
3. With regard	to the protest against payment of (an) addition	nal fee(s) under Rule 40.2,	the applicant is	notified that:	
applica applica	test together with the decision thereon has bee nt's request to forward the texts of both the pro	test and the decision therec	on to the designa	ated Offices.	
no deci	sion has been made yet on the protest; the app	plicant will be notified as soo	on as a decision	is made.	
International Burea application, or of the	xpiration of 18 months from the priority date, th au. If the applicant wishes to avoid or postpone he priority claim, must reach the International B tion of the technical preparations for internatior	publication, a notice of with ureau as provided in Rules	ndrawal of the in	ternational	,
International Burea international prelim	r submit comments on an informal basis on the au. The International Bureau will send a copy of ninary examination report has been or is to be e before the expiration of 30 months from the prio	f such comments to all designstablished. These commen	gnated Offices ι	unless an	
examination must date (in some Office	from the priority date, but only in respect of sor be filed if the applicant wishes to postpone the ces even later); otherwise, the applicant must, we the national phase before those designated Offi	entry into the national phas vithin 20 months from the	e until 30 monti	hs from the priori	ity
In respect of other months.	designated Offices, the time limit of 30 months	s (or later) will apply even i	f no demand is f	filed within 19	

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Josef Ullrich

Authorized officer

Form PCT/ISA/220 (January 2004)

(See notes on accompanying sheet)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

in these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international pbulication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When? <



Within 2 months from the date of transmittal of the international search report or 15 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been its filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

Notes to Form PCT/ISA/220 (first sheet) (January 1994)

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- Where originally there were 15 claims and after amendment of all claims there are 11]:
 Claims 1 to 15 replaced by amended claims 1 to 11.
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the International appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

Notes to Form PCT/ISA/220 (second sheet) (January 1994)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220				
X-16065	ACTION as well	as, where applicable, item 5 below.				
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)				
PCT/US2005/000019 18/01/2005 22/01/2004						
Applicant						
ELI LILLY AND COMPANY						
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Searching Aut ansmitted to the International Bureau.	hority and is transmitted to the applicant				
This International Search Report consists	of a total of sheets.					
X It is also accompanied by	a copy of each prior art document cited in this	report.				
	international search was carried out on the ba ess otherwise indicated under this item.	sis of the international application in the				
The international this Authority (Ru		ation of the international application furnished to				
b. With regard to any nucle	otide and/or amino acid sequence disclosed	in the international application, see Box No. I.				
2. Certain claims were fou	nd unsearchable (See Box II).					
3. Unity of invention is lac	king (see Box III).					
4. With regard to the title,						
X the text is approved as su	bmitted by the applicant.					
the text has been established by this Authority to read as follows:						
5. With regard to the abstract,						
l 😑 ¨	the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant					
	om the date of mailing of this international sear					
6. With regard to the drawings,						
a. the figure of the drawings t o be p	published with the abstract is Figure No.					
as suggested by	the applicant.					
as selected by thi	s Authority, because the applicant failed to su	ggest a figure.				
	s Authority, because this figure better characte	erizes the invention.				
b none of the figures is to b	e published with the abstract.					

Form PCT/ISA/210 (first sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No PCT/US2005/000019

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07J73/00 A61K31/56 A61P5/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data, EMBASE, BIOSIS

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 761 669 A (ELI LILLY AND COMPANY) 12 March 1997 (1997-03-12) claim 1 page 43; example 11b	1-21
Y	GRESE T A ET AL: "Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 41, no. 8, 1998, pages 1272-1283, XP002208889 ISSN: 0022-3263 page 1274; compound 4	1-21

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: A' document defining the general state of the art which is not considered to be of particular relevance E' earlier document but published on or after the international filling date L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O' document referring to an oral disclosure, use, exhibition or other means P' document published prior to the international filling date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document in member of the same patent family
Date of the actual completion of the international search 1 June 2005	Date of mailing of the international search report 08/06/2005
Name and mailing address of the ISA European Patent Office, P.B 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Steendijk, M

1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/000019

	stion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
,	WO 03/053977 A (ORTHO-MCNEIL PHARMACEUTICAL, INC) 3 July 2003 (2003-07-03) claim 1	1-21

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2005/000019

Patent document cited in search report		Publication date		Patent family member(s)		Publication date	
EP 0761669	Α	12-03-1997	AT	197712	T	15-12-2000	
			ΑU	705454	B2	20-05-1999	
			ΑU	6959096	Α	27-03-1997	
			BR	9610356	Α	06-07-1999	
			CA	2230974	A1	13-03-1997	
			CN	1201392	Α	09-12-1998	
			CZ	9800678	A 3	17-06-1998	
			ÐΕ		D1	28-12-2000	
			ÐΕ	69611015	T2	10-05-2001	
			DK	761669	T3	11-12-2000	
			EΑ		B1	25-06-2001	
			EP		A2	12-03-1997	
			ES		T3	01-02-2001	
			GR		T3	30-04-2001	
			HU	9802213		01-02-1999	
			ΙL	123560	Α	10-02-2002	
			ΙL	140162	Α	10-02-2002	
			JP	11514347	T	07-12-1999	
			NO	980936	Α	07-05-1998	
			NZ	318183	Α	24-09-1998	
			PL	325479	A 1	20-07-1998	
			PT	761669	T	30-04-2001	
			SI	761669	T1	30-04-2001	
			TR	9800387	T1	21-05-1998	
			WO	9709044	A1	13-03-1 99 7	
			US	6133288	Α	17-10-2000	
			US	5726186	Α	10-03-1998	
			US	6004971	Α	21-12-1999	
WO 03053977	A	03-07-2003	AU	2002362041	A1	09-07-2003	
			BR	0215152		19-10-2004	
			CA	2471107	A1	03-07-2003	
			EP	1467998		20-10-2004	
			WO	03053977	A 1	03-07-2003	
			US	2003216463	A1	20-11-2003	
			US	2004259915	A 1	23-12-2004	



PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No International filing date (day/month/year) Priority date (day/month/year) 22.01.2004 PCT/US2005/000019 18.01.2005 International Patent Classification (IPC) or both national classification and IPC C07J73/00, A61K31/56, A61P5/32 Applicant ELI LILLY AND COMPANY 1. This opinion contains indications relating to the following items: Box No 1 Basis of the opinion ☐ Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability □ Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. 3.

Na	ame	and	mailing	address	of	the	ISA:

Authorized Officer

)

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Steendijk, M

Telephone No +49 89 2399-8460



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2005/000019

_	Box N	o. Basis of the opinion
1.		egard to the language , this opinion has been established on the basis of the international application in iguage in which it was filed, unless otherwise indicated under this item.
	la	nis opinion has been established on the basis of a translation from the original language into the following nguage , which is the language of a translation furnished for the purposes of international search nder Rules 12.3 and 23.1(b)).
2.	With reneces	egard to any nucleotide and/or amino acid sequence disclosed in the international application and sary to the claimed invention, this opinion has been established on the basis of:
	a. type	of material:
		a sequence listing
		table(s) related to the sequence listing
	b. forn	nat of material:
		in written format
		in computer readable form
	c. time	of filing/furnishing:
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.	há co	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto is been filed or furnished, the required statements that the information in the subsequent or additional spies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-21

No: Claims

Inventive step (IS)

Yes: Claims

No: Claims

1-21

Industrial applicability (IA)

Yes: Claims

1-21

No: Claims

2. Citations and explanations

see separate sheet

 The present application relates to sulfonyl substituted 6-oxa or 6-thia-chrysen-2-ol derivatives having estrogen receptor modulating activity as well as intermediates for such compounds.

2) Cited documents:

D1: EP-A-0 761 669

D2: J. ORG. CHEM., vol. 41, no. 8, 1998, pages 1272-1283

D3: WO 03/053977 A

3) Novelty

Documents D1 and D2 describe estrogen receptor modulating compounds with related basic structure, which lack however the characteristic sulfonyl substitution or precursor therefore.

Document D3 describes estrogen receptor modulating compounds which may carry a sulfonyl substitution, but which comprise a different core structure.

4) Inventive step

Documents D1 and D2 represent the closest prior art, in view of which the problem solved according to the present application would appear the provision of alternative agents with estrogen receptor modulating activity (compare reported data for examples 1 and 3 on pages 34,36,37).

Merely as solution to the problem of providing alternative agents the presently defined modification in the form of a sulfonyl substitution to compouds of the type described in D1/D2 would seem obvious to the person skilled in the art as D1 itself indicates that at the relevant positions may various substitutions may occur, whereas D3 describes closely related compounds with similar activity which may indeed carry sulfonyl substitutions at the relevant positions.